Granisetron intranasal - Aerial BioPharma

Drug Profile

Granisetron intranasal - Aerial BioPharma

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Aerial BioPharma
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 25 Feb 2016 No recent reports on development identified - Phase-III for Chemotherapy and Radiotherapy induced nausea and vomiting in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top